Institut Paoli-Calmettes, Marseille: Cancer Care Profile

Institut Paoli-Calmettes is a long-established cancer institution whose origins date to the 1920s. It developed as a regional centre for cancer care and is now part of UNICANCER, the French network of specialist, private not-for-profit cancer centres. Its role combines patient care, research and teaching rather than the broad services of a general hospital.

The centre serves Marseille and the wider south-eastern French region. Its hospital activities include inpatient care, outpatient consultations, diagnostic assessment and day-treatment services. These settings support different levels of treatment intensity, from consultations and scheduled infusions to complex admissions. Patients should not assume that every treatment requires hospitalisation or that all specialist services can be accessed immediately.

The institute is known for haematology, stem cell transplantation and its CAR-T programme, alongside care for solid tumours. Its research environment includes the CRCM, which connects laboratory investigation with clinical cancer research. Multidisciplinary assessment brings together relevant specialists to consider diagnosis and treatment choices. This structure supports coordinated care, but recommendations still depend on each patient's clinical circumstances and the evidence for the proposed treatment.

Breast cancer care can involve surgery, radiation therapy and systemic treatment selected according to stage, hormone receptors and other tumour features. Colon cancer pathways may combine surgery and drug treatment, with molecular testing helping guide options in advanced disease. Prostate cancer management depends on disease extent, symptoms, previous treatment and personal priorities; an assessment may consider monitoring as well as active treatment, rather than automatically recommending an intervention.

Blood cancers are a notable area of activity, including leukaemias, lymphomas and other haematological malignancies. Depending on the diagnosis, care may involve drug treatment, stem cell transplantation or CAR-T therapy. Pancreatic cancer is another identified programme, where specialist review is important for judging operability, planning systemic treatment and addressing nutrition or symptoms. These listed specialties describe areas of practice, not a ranking or a guarantee that a particular procedure is suitable.

Surgery and radiation therapy are available within the centre's oncology services. Surgery may be intended to remove a localised tumour, establish a diagnosis or manage complications. Radiation therapy may be used alone or with other treatments. The specific technique, sequence and number of visits should be confirmed after review rather than inferred from the centre's general service list.

Systemic treatments include chemotherapy, immunotherapy and targeted therapy. Immunotherapy is appropriate for some cancers and treatment settings, while targeted drugs usually depend on a relevant biological feature or an established indication. Patients may need pathology review or additional molecular testing before a recommendation can be made. Access also depends on authorisation and funding arrangements.

Stem cell transplantation and CAR-T therapy require specialist selection and substantial preparation. CAR-T is not a general treatment for all cancers; established uses mainly concern selected blood cancers. Assessment considers the exact diagnosis, prior therapies, fitness and potential risks. Treatment can involve serious complications and requires a defined monitoring and emergency-care plan.

Supportive care remains important alongside anticancer treatment, including symptom control, nutritional assessment and psychological support where needed. Patients should ask which services will be included in their pathway and who will coordinate follow-up. A treatment available at the institute may still be unsuitable, unnecessary or unavailable within a particular patient's proposed timetable.

The institute's clinical research portfolio is described as including around 250 active oncology clinical trials. This figure is indicative and changes as studies open, close or move into follow-up. An active study is not necessarily recruiting, and a listed trial may have no available places for a particular diagnosis or treatment group. Research activity should not be interpreted as proof of better outcomes for an individual patient.

International patients can ask the relevant disease team to assess potential trial eligibility using their records. Screening may require confirmation of pathology, biomarkers, previous treatments and organ function, followed by an in-person assessment. The team must also confirm whether participation from abroad is feasible under the study's rules and funding arrangements. Before consenting, ask about randomisation, alternatives, visit frequency, foreseeable risks and responsibility for costs; an experimental treatment is not guaranteed to help.

Begin through the institute's official website and ask for the appropriate referral route for your diagnosis and country of residence. Request an initial review before booking travel, and establish whether it provides advice, a consultation appointment or a treatment offer. Clarify whether further tests in Marseille will be necessary and whether your current team should continue treatment while the referral is assessed.

Plan the whole care episode, not just the first appointment. Confirm expected time in Marseille, possible hospital admission, accompanying-person requirements and access to urgent care after discharge. Ask how records and recommendations will be shared with clinicians at home. For transplantation, CAR-T or trial participation, prolonged local monitoring may be necessary. Do not stop or postpone existing treatment without agreement from your treating team.

Contact details below come from the hospital's own published international patient information.

Location: Marseille, France

Email: No public international e-mail address is published; use the website enquiry form.

Phone: +33 4 91 22 33 33

Website: https://www.institutpaolicalmettes.fr

Languages supported: French, English, Italian, Arabic

Remote second opinion: Available

Always confirm current contact details on the hospital's own website before sending medical records, and never send documents to an address you have not verified.